Antibody-drug conjugates in solid tumors; new strategy for cancer therapy
Toshiaki Takakura1, Toshio Shimizu1, Nobuyuki Yamamoto1
1Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Faculty of Medicine, 811-1 Kimiidera, Wakayama, Wakayama 641-8510, Japan.
Abstract:
Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors.
Insights
Antibody-drug conjugates (ADCs) offer targeted cancer therapy by linking monoclonal antibodies to cytotoxic payloads. While approved ADCs show survival benefits, further understanding is needed to overcome development challenges and improve patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment.
- ADCs utilize monoclonal antibodies for targeted delivery of cytotoxic payloads to cancer cells.
- Several ADCs are approved for hematologic and solid tumors, demonstrating survival benefits.
Purpose of the Study:
- To provide a concise overview of the structure and mechanism of antibody-drug conjugates.
- To review the clinical data of currently approved ADCs in solid tumors.
- To highlight the challenges and future directions in ADC development.
Main Methods:
- Review of existing literature on ADC structure and function.
- Analysis of clinical trial data for approved ADCs in solid tumors.
- Discussion of the mechanism of action for targeted cancer therapy.
Main Results:
- ADCs comprise a monoclonal antibody, linker, and payload for targeted cancer cell destruction.
- Approved ADCs have shown clinically meaningful survival benefits in various cancers.
- Challenges in ADC development necessitate further research for improved efficacy and patient outcomes.
Conclusions:
- ADCs are a promising therapeutic class with demonstrated efficacy in cancer treatment.
- A deeper understanding of ADC mechanisms and challenges is crucial for advancing the field.
- Continued research and development are essential to optimize ADC therapy for better patient outcomes.
More Related Videos
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...